Sep 1, 2021
On August 18, 2021, ICER released its draft evidence report, “Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value.” This is the first step in ICER’s process that, if the announced schedule holds, will lead to the release of final evidence report in...
Aug 23, 2021
On August 17, 2021, ICER issued a Final Evidence Report on the clinical and cost-effectiveness of new treatments for atopic dermatitis (more commonly referred to as eczema). After following its typical process for gathering and reviewing data, ICER concluded that the...
Aug 5, 2021
On August 5, 2021, ICER issued its Final Evidence Report on aducanumab, a first-of-its-kind medication created to treat Alzheimer’s disease. Following its typical process for gathering information – which included the solicitation of public comments and a public...
Jul 26, 2021
By Robert Popovian & Mark Atalla July 16, 2021 Recently the U.S. Food and Drug Administration granted accelerated approval to aducanumab (Aduhelm), the first Alzheimer’s Disease treatment since 2003. While there has been significant discussion about aducanumab’s...
Jul 14, 2021
On Monday, July 19th, the Pioneer Institute and the Pacific Research Institute (PRI) will host a virtual webinar, titled: Policy Measures on Drug Value: Does ICER’s Approach Improve Patient Access & Equity? The event will feature prominent experts in a discussion...
Jul 14, 2021
Patients Rising – in coordination with Gravis Marketing, a leading market research and polling firm – recently conducted a survey to better understand American voters’ views on national health issues. The data from the survey – which was conducted in late April and...
